Crestor International Purchase Legalities: What U.S. Patients Need to Know in 2026

Is It Legal to Buy Crestor from Another Country?

Purchasing Crestor from a foreign pharmacy and importing it into the United States is prohibited under the Federal Food, Drug, and Cosmetic Act (FD&C Act), which restricts importation of unapproved drugs. However, the FDA maintains a long-standing enforcement discretion policy that allows personal importation of a 90-day supply when specific conditions are met.

The FDA's Compliance Policy Guide (CPG Sec. 110.310) states that agents may consider exercising enforcement discretion when a product poses no significant safety risk, is for personal use, and the individual provides written confirmation that the drug is for personal treatment. The policy does not create a legal right to import. U.S. Customs and Border Protection retains the authority to seize any shipment that crosses the border, and seized medication is rarely returned. [1]

What the Law Actually Says

The FD&C Act, specifically 21 U.S.C. § 331, prohibits introducing into commerce any drug that lacks FDA approval for the labeling and form in which it is sold. Foreign rosuvastatin products, even those manufactured by AstraZeneca or a licensed generic maker, carry foreign labeling and are considered "unapproved" under U.S. Law.

No federal statute carves out a patient exception. The enforcement discretion described in CPG Sec. 110.310 is an internal agency policy document, not a regulation with legal force. Congress debated a broad drug importation bill as recently as 2023, but as of 2026 no legislation has passed that legalizes personal importation at the federal level. [2]

What Enforcement Discretion Means in Practice

In practical terms, the FDA focuses its enforcement on commercial-scale importers, counterfeit drug operations, and suppliers of controlled substances. Personal shipments of a statin tablet for a known cardiovascular indication rarely trigger prosecution.

U.S. Customs data published by the FDA show that prescription drug shipments are routinely stopped at mail facilities in cities including New York, Miami, Los Angeles, and Chicago. A stopped shipment typically results in a "detention notice" from Customs, not criminal charges. The recipient loses the medication and the money paid. [3]

How the 90-Day Personal Importation Rule Works

The 90-day supply threshold is the clearest protective boundary in FDA's discretion policy. Ordering more than a 90-day supply substantially increases the probability of seizure, and it moves the transaction closer to a commercial importation pattern that the agency actively prosecutes.

The Five Conditions FDA Looks For

FDA CPG Sec. 110.310 describes five factors agents weigh:

1. The product presents no unreasonable risk to the patient.
2. The product is for personal use only, not for resale.
3. The patient attests in writing that the drug is for personal treatment.
4. The patient provides contact information for the U.S.-based licensed physician who manages their care.
5. The quantity imported is consistent with personal use (generally no more than a 90-day supply).

Rosuvastatin is a widely used, well-characterized lipid-lowering agent with a safety profile documented across more than 20 years of post-market surveillance and trials including JUPITER (N=17,802) [4]. Meeting conditions one and two is therefore straightforward for most patients on a stable statin regimen.

What Happens at the Border

When a shipment is flagged, Customs and Border Protection (CBP) issues a Form CBP 28 or Form CBP 29 requesting information or proposing to refuse entry. The patient then has an opportunity to respond, but the agency is under no obligation to release the goods. Rosuvastatin tablets are not controlled substances, so criminal referral is uncommon for personal quantities, but it remains theoretically possible.

Why Generic Rosuvastatin Changes the Calculus Entirely

AstraZeneca's patents on Crestor expired in 2016. At least eight FDA-approved generic manufacturers now market rosuvastatin calcium in the United States. The price differential between branded Crestor and the generic has narrowed the argument for international purchase to nearly zero for most patients. [5]

Current U.S. Generic Pricing

At major retail pharmacies, a 30-day supply of rosuvastatin 10 mg generic costs between $10 and $18 without insurance. GoodRx and similar discount platforms list prices as low as $9 at certain chain pharmacies for a 90-day supply. The average branded Crestor 30-tablet pack retailed at $285, $350 in late 2025, making generic substitution a savings of more than 90%.

Canada, the most common international source for U.S. Patients, lists branded Crestor at approximately CAD $85 (roughly USD $62) for 90 tablets of 10 mg. Generic rosuvastatin in Canada runs approximately CAD $30 (roughly USD $22) for 90 tablets. Generic rosuvastatin in the U.S. At $10, $18 per 30 days costs $30, $54 for a 90-day supply, which is comparable to or cheaper than the Canadian generic after shipping and currency conversion. The international route offers no meaningful price advantage for most patients once a domestic generic is dispensed. [6]

When International Pricing Still Matters

A narrow group of patients face circumstances where international sourcing may appear appealing. These include patients who cannot tolerate standard generic fillers (requesting a specific branded formulation), those on high-dose rosuvastatin 40 mg where even generic pricing reaches $30, $45 monthly, and patients in insurance coverage gaps. For those individuals, manufacturer assistance programs and domestic discount cards remain the legally safer first step.

Identifying Safe International Pharmacy Sources

If a patient proceeds with international purchase despite the legal field, source verification is the single most consequential safety step. The World Health Organization estimates that 50% of medicines sold through websites that conceal their physical address are counterfeit. [7]

NABP and CIPA Accreditation

Two accreditation bodies provide meaningful vetting:

NABP (.pharmacy program). The National Association of Boards of Pharmacy awards the ".pharmacy" domain suffix and its "Verified Internet Pharmacy Practice Sites" (VIPPS) seal only to pharmacies that meet U.S. Licensure standards. NABP also publishes a "Not Recommended" list of websites that sell prescription drugs unsafely. Checking an international pharmacy against the NABP database before ordering is a minimum safety step.

CIPA (Canadian International Pharmacy Association). CIPA-accredited pharmacies are licensed by Canadian provincial regulatory authorities and dispense only Health Canada-approved products. CIPA publishes its member list publicly. Canadian pharmacies that are not CIPA members lack the regulatory oversight that reduces counterfeit risk.

Patients should never order from a website that offers prescription drugs without requiring a valid prescription. Legitimate pharmacies in Canada, the UK, Australia, and the EU require a current prescription issued by a licensed physician. A site that bypasses this step is operating outside its own country's laws.

Red Flags for Counterfeit Operations

• Price dramatically below even the lowest verified comparators (below $5 per 30 tablets of any statin dose is implausible).
• No physical address listed, or an address that does not match a licensed pharmacy in the claimed country.
• Unsolicited email marketing offering prescription drugs.
• Payment accepted only via wire transfer or cryptocurrency.
• No licensed pharmacist available by phone or chat for consultation.

State-Level Importation Programs: A Different Pathway

Several U.S. States have pursued FDA-approved Section 804 Importation Programs (SIPs) under the authority granted by the 2003 Medicare Modernization Act. As of early 2026, Florida, Colorado, New Hampshire, Texas, and several other states have submitted or received conditional approval for wholesale importation programs that source drugs from Canada for state-funded health programs. [8]

These programs are not yet open to individual consumers purchasing for personal use. They are designed for state Medicaid programs, prisons, and public employee health plans. Individual patients cannot access these pipelines directly. However, their existence signals that the policy field is shifting, and expanded individual access programs may emerge within the next few years.

Legitimate Ways to Reduce Crestor or Rosuvastatin Costs in the U.S.

Manufacturer Savings Programs

AstraZeneca operates the AZ&Me Prescription Savings Program, which offers Crestor at no cost to eligible patients who are uninsured or underinsured and meet income criteria. Income thresholds are updated annually. Patients earning up to 600% of the federal poverty level may qualify. [9]

AstraZeneca also offers a commercial copay savings card that can reduce out-of-pocket cost to $0 per 30-day prescription for insured patients with commercial (non-government) insurance. The card does not apply to Medicare, Medicaid, or TRICARE beneficiaries.

Generic Substitution

Asking a prescriber to write "rosuvastatin calcium" rather than "Crestor" allows the pharmacy to dispense any FDA-approved generic. All generics must meet the same bioequivalence standards as the branded product, per 21 CFR Part 320. The FDA's Orange Book lists all approved rosuvastatin generics with their therapeutic equivalence ratings. [5]

Pharmacy Discount Programs

GoodRx, RxSaver, and Blink Health negotiate prices with pharmacy benefit managers and pass savings to consumers. These are not insurance, but they consistently price 30-tablet rosuvastatin 10 mg between $9 and $18. The prices update in real time and vary by zip code.

HSA and FSA Eligibility

Rosuvastatin is an eligible medical expense under IRS Publication 502. Both Health Savings Accounts (HSA) and Flexible Spending Accounts (FSA) cover prescription drug costs. Using pre-tax HSA/FSA dollars effectively reduces cost by 22 to 37% depending on the patient's marginal income tax bracket. [10]

340B Drug Pricing Program

Patients receiving care at federally qualified health centers (FQHCs), qualifying hospitals, or other covered entities may access drugs through the 340B program, which caps manufacturer prices substantially below retail. Eligible patients can confirm 340B status at their clinic and request a 340B pharmacy dispense.

What the Clinical Evidence Says About Rosuvastatin

Understanding why correct, verified sourcing matters requires understanding what is at stake therapeutically. Rosuvastatin is not a discretionary supplement. For patients with established cardiovascular disease or high 10-year risk, it is a primary preventive agent with a large outcome trial supporting its use.

JUPITER Trial (2008)

The JUPITER trial (Justification for the Use of Statins in Prevention, N=17,802) assigned apparently healthy adults with LDL below 130 mg/dL but elevated high-sensitivity CRP (hsCRP above 2.0 mg/L) to rosuvastatin 20 mg daily or placebo. At a median follow-up of 1.9 years the trial was stopped early for efficacy. Rosuvastatin reduced LDL by 50%, hsCRP by 37%, and the composite cardiovascular endpoint (myocardial infarction, stroke, arterial revascularization, hospitalization for unstable angina, or cardiovascular death) by 44% (HR 0.56; 95% CI 0.46 to 0.69; P<0.00001). [4]

The New England Journal of Medicine published these results in November 2008. The trial's principal investigator, Dr. Paul Ridker, stated: "We demonstrated that rosuvastatin significantly reduced the incidence of major cardiovascular events" in patients previously considered at low risk by lipid criteria alone.

ACC/AHA Cholesterol Guidelines

The 2019 ACC/AHA Guideline on the Primary Prevention of Cardiovascular Disease identifies high-intensity statin therapy, which rosuvastatin 20 to 40 mg represents, as a Class I recommendation for adults aged 40 to 75 with a calculated 10-year ASCVD risk of 10% or higher, and a Class IIa recommendation for those with risk between 7.5% and 10%. [11]

The guideline document states: "High-intensity statin therapy should be initiated or continued as first-line therapy in women and men less than or equal to 75 years of age who have clinical ASCVD, unless contraindicated."

Therapeutic continuity matters for this drug class. A gap in rosuvastatin therapy caused by a seized international shipment, a customs delay, or receipt of a counterfeit product that contains no active ingredient could directly increase cardiovascular risk in patients who depend on this medication.

How HealthRX Approaches Statin Access

HealthRX providers can prescribe rosuvastatin through a telehealth visit and send the prescription to any U.S.-licensed pharmacy, including mail-order pharmacies that compete on price. For most patients, the combination of a GoodRx coupon at a discount pharmacy, generic substitution, and a 90-day supply order reduces monthly cost to under $8.

Patients who demonstrate clinical need and meet income criteria can be referred to the AZ&Me patient assistance program or appropriate 340B-covered clinics within their region. HealthRX does not recommend or support international pharmacy purchases, given the legal exposure, seizure risk, and the practical reality that domestic generic pricing has eliminated most of the cost argument for importing rosuvastatin.